## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A ~~cosmetic method for improving aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema~~ method of reduction of the visible signs of fine lines on the skin in an individual in need thereof,

said method comprising contacting the skin of said individual with a composition comprising at least one ACE inhibitor and/or angiotensin II receptor antagonist, or a cosmeceutically acceptable salt thereof,

~~wherein said method is for reduction of~~ thereby reducing the visible signs of fine lines on the skin.

2. (Canceled)

3. (Currently amended) The ~~cosmetic~~ method according to claim 2, wherein said method is ~~for the~~ a method of treatment of wrinkles.

4. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said composition comprises at least one ACE inhibitor.

5. (Currently amended) The ~~cosmetic~~ method according to claim 4, wherein said ACE inhibitor is a non-thiol-containing ACE inhibitor.

6. (Currently amended) The ~~cosmetic~~ method according to claim 4, wherein said ACE inhibitor is a lipophilic ACE inhibitor.

7. (Currently amended) The ~~cosmetic~~ method according to claim 4, wherein said ACE inhibitor is an ACE inhibitor binding the zinc-binding ligand of the active site of ACE via a phosphinyl group or a carboxyl group.

8. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said composition comprises at least one angiotensin II receptor antagonist.

9. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said ACE inhibitor is lisinopril, or a cosmeceutically acceptable salt thereof.

10. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said composition comprises at least two ACE inhibitor(s) and/or angiotensin II receptor antagonist(s).

11. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.01-100 mg/kg.

12. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said composition further comprises a cosmeceutically-acceptable topical carrier.

13. (Currently amended) The ~~cosmetic~~ method according to claim 1, wherein said composition is formulated as a cream or lotion.

14. (Currently amended) The ~~cosmetic~~ method according to claim 1, which comprises repeatedly performing said contacting over an extended period of time.

15. (Currently amended) Method for the treatment of ~~skin ageing or~~ wrinkling, comprising administering an ACE inhibitor and/or angiotensin II receptor antagonist to an individual in need thereof.

16. (Currently amended) The method according to claim 15, wherein said skin ageing or wrinkling is considered premature as compared to normal ~~skin ageing and~~ wrinkling.

17. (Currently amended) The method according to claim 15 wherein the ACE inhibitor and/or angiotensin II receptor antagonist is ~~lisinopril~~ selected from the group consisting of captopril, enalaprilat and pharmaceutically acceptable salts thereof.

18. (Previously presented) The method according to claim 15, wherein the medicament is in a formulation for topical administration to the skin.

19. (Previously presented) The method according to claim 15, wherein the medicament is administered at least once daily.

20. (Previously presented) The method according to claim 15, wherein the medicament is administered in a concentration equivalent of from 0.01 to 100 mg per kg.

21-22 (Canceled)

23. (New) The cosmetic method according to claim 1, wherein said ACE inhibitor is captopril, or a cosmeceutically acceptable salt thereof.

24. (New) The cosmetic method according to claim 1, wherein said ACE inhibitor is enalaprilat, or a cosmeceutically acceptable salt thereof.

25. (New) A composition suitable for application onto skin, consisting of captopril and in the range of 10 to 99.9% by weight of dermatologically acceptable carriers, wherein the carriers are anhydrous.

26. (New) A composition suitable for application onto skin, consisting of enalaprilat and in the range of 10 to 99.9% by weight of dermatologically acceptable carriers, wherein the carriers are anhydrous.

27. (New) The method according to claim 1, wherein the ACE inhibitor and/or angiotensin II receptor antagonist is selected from the group consisting of Alacepril, Delapril, Benazepril, Cilazapril, Captopril, Enlapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, Isradipin, perindopril, spirapril, temocapril, Enalapril, losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Zofenapril, Isradipin,

Candesartancilexetil, alatriopril, altiopril calcium, ancovenin, benazepril, hydrochloride, benazeprilat, benzazepril, benzoylcaptopril, captopril-cysteine, captopriglutathione, ceranapril, ceranopril, ceronapril, cilazaprilat, converstatin, delapril-diacid, enalaprilat, enalkiren, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4,idapril, indolapril, indolaprilat, libenzapril, lyciumin A, lyciumin B, mixanpril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, perindoprilat, pivalopril, pivopril, quinapril hydrochloride, Pentopril, pentoprilat, quinaprilat, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril hydrochloride, temocapril hydrochloride, teprotide, trandolaprilat, utibapril, zabicipril, zabiciprilat, losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Isradipin, Candesartancilexetil, olmesartan, medoxomil, zofenoprilat, Asp-Arg-Val-Tyr-Val-His-Pro-Phe; Asn-Arg-Val-Tyr-Val-His-Pro-Phe; Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe; Glu-Arg-Val-Tyr-Ile-His-Pro-Phe; Asp-Lys-Val-Tyr-Ile-His-Pro-Phe; Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe; Asp-Arg-Val-Thr-Ile-His-Pro-Phe; Asp-Arg-Val-Tyr-Leu-His-Pro-Phe; Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe; Asp-Arg-Val-Tyr-Ile-His-Ala-Phe; Asp-Arg-Val-Tyr-Ile-His-Pro-Tyr; Pro-Arg-Val-Tyr-Ile-His-Pro-Phe; Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe; Asp-Ar-Val-Tyr; 2-Ile-His-Pro-Phe; Asp-Arg-norLeu-Tyr-Ile-His-Pro-Phe; Asp-Arg-Val-Tyr-norLeu-His-Pro-Phe; Asp-Arg-Val-homoSer-Tyr-Ile-His-Pro-Phe; Val-Trp and cosmeceutically acceptable salts thereof.

28. (New) The method according to claim 1, wherein the ACE inhibitor and/or angiotensin II receptor antagonist is an ACE inhibitor selected from the group consisting of quinapril, quinaprilat, trandolaprilat, trandolapril, moexipril, moexiprilat, fosinoprilat, fosinopril,

benazeprilat, benazepril, enalaprilat, enalapril, captopril, lisinopril, ramaprilat, ramapril and cosmeceutically acceptable salts thereof.